
    
      40 eligible patients will be enrolled. A two-stage design efficacy and safety of bendamustine
      and capecitabine will be evaluated following recruitment of the first 20 patients. Upon
      favorable results a further 20 patients will be recruited to reach the target population of
      40 evaluable patients.

      Pretreatment for eligible patients must include anthracyclines and/or taxanes.
    
  